168 results on '"Hilleret, Marie-Noëlle"'
Search Results
2. The role and evolution of partial splenic embolization over three decades: A multicentric retrospective single cohort study of 90 patients from French nationwide experience
3. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial
4. Impact of Type 2 Diabetes on the Accuracy of Noninvasive Tests of Liver Fibrosis With Resulting Clinical Implications
5. Inevitability of disease recurrence after liver transplantation for NAFLD cirrhosis
6. AFP score and metroticket 2.0 perform similarly and could be used in a “within-ALL” clinical decision tool
7. Early intrahepatic recurrence of hepatitis B virus infection in liver transplant recipients despite antiviral prophylaxis
8. Helpfulness of the liver disease scores in cardiac surgery for cirrhotic patients
9. Bulevirtide Combined with Pegylated Interferon for Chronic Hepatitis D
10. GS-002 48-week off-therapy efficacy and safety of bulevirtide in combination with pegylated interferon alfa-2a in patients with chronic hepatitis delta: final results from the phase 2b, open-label, randomised, multicentre study MYR204
11. FRI-370 Bulevirtide efficacy and safety in chronic hepatitis delta patients on liver transplant waiting list
12. FRI-371 Undetectable HDV RNA at 24 weeks of treatment with combination therapy is an important predictor of maintained response off-therapy
13. WED-410 Sustained virological response after treatment with Bulevirtide in HDV patients. Data from the french multicenter real-life cohort
14. SAT-389 HBV and HBsAg strongly reshape the phenotype, function and metabolism of DCs according to patients’ clinical stage
15. WED-391 Long-term virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with bulevirtide monotherapy for up to 120 weeks: a retrospective multicenter european study (save-d)
16. OS-120 Bulevirtide monotherapy prevents liver decompensation and reduces mortality in patients with HDV-related cirrhosis: a case control study with propensity score weighted analysis
17. GS-010 Early liver transplantation for severe alcohol-related hepatitis: long-term data of the french-belgian controlled study (QuickTrans)
18. SAT-048 Long-term mortality and risk factors associated with mortality after liver transplantation in the modern era
19. TOP-005 Immune checkpoint inhibitors after liver transplantation: the key role of immunosuppression management
20. SAT-396 Differences in the intrahepatic expression of immune checkpoint molecules on T cells and natural killer cells in chronic HBV patients
21. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation
22. Early liver transplantation for severe alcohol-related hepatitis not responding to medical treatment: a prospective controlled study
23. Liver transplantation-associated lung cancer in smokers: Results of an early CT detection program
24. Early hepatocellular carcinoma detection using magnetic resonance imaging is cost-effective in high-risk patients with cirrhosis
25. International study on the outcome of locoregional therapy for liver transplant in hepatocellular carcinoma beyond Milan criteria
26. Long term results of liver transplantation for alpha-1 antitrypsin deficiency
27. Autoimmune hepatitis recurrence after liver transplantation: “Les jeux sont faits”.
28. Autoimmune hepatitis recurrence after liver transplantation: “Les jeux sont faits”
29. The epidemiology of Budd–Chiari syndrome in France
30. Reflex testing automatization for HBsAg carriers: A novel era for hepatitis delta management
31. HDV-RNA decline less than 1 log after 6 months of BLV 2 mg monotherapy could define poor-response and lead to therapeutic decision. Data from real-life cohort
32. Long-term outcome following liver transplantation for chronic liver disease in intensive care unit: the French nationwide experience
33. Is treatment with Bulevirtide 10 mg useful in poor responder patients to 2 mg? Results from the French multicenter early access program
34. Incidence of hepatitis D virus super-infection in HBsAg positive patients (The Inci-D cohort study)
35. Early intrahepatic recurrence of HBV infection in liver transplant recipients despite antiviral prophylaxis
36. Consider schistosomiasis screening in hepatitis B patients from endemic regions: a hepatic comorbidity that should not be neglected
37. Virological and clinical outcomes of patients with HDV-related compensated cirrhosis treated with Bulevirtide monotherapy: the retrospective multicenter European study (Save-D)
38. Long‐term outcome of liver transplantation for autoimmune hepatitis: A French nationwide study over 30 years
39. Liver transplantation for autoimmune hepatitis: Pre‐transplant does not predict the early post‐transplant outcome
40. Survival and prognostic factors after adjuvant 131iodine-labeled lipiodol for hepatocellular carcinoma: a retrospective analysis of 106 patients over 20 years
41. Liver transplantation for NAFLD cirrhosis: Age and recent coronary angioplasty are major determinants of survival
42. Recurrence of primary sclerosing cholangitis after liver transplantation: a french cohort study including 571 patients
43. Impact of type 2 diabetes on the accuracy of non-invasive tests of liver fibrosis: a comprehensive analysis of 1, 051 biopsy proven NAFLD patients showing clinical implications
44. New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination-a vascular liver disease group (VALDIG) initiative
45. Treatment with Bulevirtide in patients with chronic HBV/HDV co-infection. Safety and efficacy at month 18 in real-world settings
46. Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria
47. Non-invasive diagnosis and follow-up in liver transplantation
48. Assessment of selective real-time PCR for quantitation of lamivudine and adefovir hepatitis B virus-resistant strains and comparison with direct sequencing and line probe assays
49. Response
50. Nonalcoholic Fatty Liver Disease, Nocturnal Hypoxia, and Endothelial Function in Patients With Sleep Apnea
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.